Codeine-Containing Cough Syrup Prescribing Options
For adult patients with distressing cough, prescribe codeine linctus (15 mg/5 mL) or codeine phosphate at 15-30 mg every 4 hours as needed, up to 4 doses in 24 hours (maximum 240 mg/24 hours), titrating to an acceptable side-effect profile. 1
Standard Dosing Regimens
The most recent NICE guidelines (2020) provide clear first-line dosing for codeine-containing antitussives 1:
- Codeine linctus (15 mg/5 mL): 15-30 mg every 4 hours as required, up to 4 doses in 24 hours
- Codeine phosphate tablets (15 mg, 30 mg): Same dosing as above
- Maximum daily dose: 30-60 mg four times daily (maximum 240 mg in 24 hours)
For more severe or refractory cough, the CHEST guidelines (2017) recommend 30-60 mg four times daily 2, though this represents the upper end of dosing and should be reserved for cases where lower doses prove inadequate.
Clinical Context for Prescribing
When to prescribe codeine:
- Only when cough is distressing and impacting quality of life 1
- After simple non-drug measures (honey, simple linctus) have failed 1
- For short-term symptomatic relief in chronic bronchitis 3, 4
- Not recommended for acute viral upper respiratory infections due to limited efficacy and side effect profile 3, 4, 5
Important caveat: Avoid cough suppressants in chronic bronchitis and bronchiectasis when productive cough is present, as they can cause dangerous sputum retention 1.
Stepwise Approach to Cough Management
The evidence supports a hierarchical approach, particularly from the NICE COVID-19 guidelines which provide the clearest algorithm 1:
- First-line: Simple measures (honey, simple linctus)
- Second-line: Codeine preparations (doses above)
- Third-line: If codeine ineffective, escalate to morphine sulfate oral solution 2.5-5 mg every 4 hours as needed 1
For patients already on regular morphine, increase the regular dose by one-third rather than adding codeine 1.
Alternative Formulations
FDA-approved codeine antitussive formulations include 6:
- Codeine phosphate 10 mg per 5 mL syrup (adult dose: 10 mL every 4 hours, maximum 6 doses/24 hours)
- Combination products with guaifenesin (codeine 10 mg + guaifenesin 100 mg per 5 mL)
Duration of Treatment
Prescribe for short-term use only - typically 7-14 days 7, 8. Real-world data shows median prescription duration of 27.5 days, but approximately 14% of patients receive codeine for >8 weeks 8, which exceeds evidence-based recommendations. If a short course doesn't produce improvement, discontinue and try alternative approaches rather than continuing indefinitely 2.
Safety Considerations and Side Effects
Common adverse effects (reported in 7.8-15% of patients) 7, 8:
- Constipation (most common)
- Drowsiness/sedation
- Headache
Critical safety warnings:
- CYP2D6 polymorphisms: Poor metabolizers get minimal benefit; ultrarapid metabolizers risk morphine toxicity 9. Consider genetic testing in patients with unexpected responses.
- Monitor individual responses carefully, as effectiveness varies significantly 10
- All adverse events in recent studies were mild and non-serious, with no treatment discontinuations required 7
Comparative Effectiveness
Recent randomized trial data (2022) demonstrates codeine's superiority over peripheral antitussives 10:
- Codeine (60 mg/day) reduced VAS scores by 35.11 ± 20.74 points
- Levodropropizine (180 mg/day) reduced VAS scores by only 19.77 ± 24.83 points (p=0.002)
- Codeine also showed superior improvements in Cough Symptom Score and Leicester Cough Questionnaire 10
However, codeine produced more treatment-related adverse events, though discontinuation rates were similar between groups 10.
Special Populations
Palliative care/lung cancer patients: For nonspecific cough in palliative stages, consider a bedtime dose of codeine or pholcodine (10 mL four times daily) to suppress cough and promote undisturbed sleep, though this is based on clinical experience rather than robust evidence 2.
When Codeine Fails
If opioid-resistant cough develops, the CHEST guidelines recommend 2:
- Trial peripherally-acting antitussives (levodropropizine 75 mg three times daily, moguisteine 100-200 mg three times daily)
- If still refractory, consider nebulized local anesthetics (lidocaine 5 mL of 0.2% three times daily) - but assess aspiration risk first